The economics of cardiac biomarker testing in suspected myocardial infarction

Clinical Biochemistry

Volumn 48, Issue 4-5, 2015, Pages 213-217

  Goodacre, Steve ^a   Thokala, Praveen ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cardiac biomarkers; Cost effectiveness; Myocardial infarction

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE MARKER; ECONOMIC EVALUATION; HEALTH CARE COST; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; LOW RISK PATIENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; BLOOD; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; ECONOMICS; MYOCARDIAL INFARCTION; PROCEDURES;

BIOMARKERS; COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; HUMANS; MYOCARDIAL INFARCTION;

EID: 84924597873     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.08.012     Document Type: Article

References (22)

1. Goodacre S., Cross E., Arnold J., Angelini K., Capewell S., Nicholl J. The health care burden of acute chest pain. Heart 2005, 91:229-230.
2. Health and Social Care Information Centre Hospital episode statistics, admitted patient care, England 2012-13 Published November 2013. http://www.hscic.gov.uk/home.
3. Department of Health Reference costs 2012-13 Published November 2013. https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013.
4. Collinson P.O., Gaze D.C., Thokala P., Goodacre S. Randomised Assessment of Treatment using Panel Assay of Cardiac markers - Contemporary Biomarker Evaluation (RATPAC CBE). Health Technol Assess 2013, 17(15).
5. Goodacre S., Thokala P., Carroll C., Stevens J., Leaviss J., Al Khalaf M., et al. Systematic review, meta-analysis and economic modelling of diagnostic strategies for suspected acute coronary syndrome. Health Technol Assess 2013, 17(1).
6. Thokala P., Goodacre S.W., Collinson P., Stevens J.W., Mills N.L., Newby D.E., et al. Cost-effectiveness of presentation and delayed troponin testing for acute myocardial infarction. Heart 2012, 98:1498-1503.
7. Bradburn M., Goodacre S., Fitzgerald P., Coats T.J., Gray A.J., Hassan T.B., et al. Inter-hospital variation in the RATPAC Trial (Randomised Assessment of Treatment using Panel Assay of Cardiac markers). Emerg Med J 2012, 29:233-238.
8. Alzuhairi K.S., Hjortshøj S., Kristensen S.R., Ravkilde J. A third troponin T blood sample is not cost-effective in patients with suspected non-ST segment elevation acute coronary syndrome. Scand J Clin Lab Invest 2011, 71:117-122.
9. Fitzgerald P., Goodacre S.W., Cross E., Dixon S. Cost-effectiveness of point-of-care biomarker assessment for suspected myocardial infarction: the RATPAC Trial (Randomised Assessment of Treatment using Panel Assay of Cardiac markers). Acad Emerg Med 2011, 18:488-495.
10. Birkhahn R.H., Haines E., Wen W., Reddy L., Briggs W.M., Datillo P.A. Estimating the clinical impact of bringing a multimarker cardiac panel to the bedside in the ED. Am J Emerg Med 2011, 29(3):304-308.
11. Dijksman L.M., Hirsch A., Windhausen F., Asselman F.F., Tijssen J.G., Dijkgraaf M.G., et al. Cost-effectiveness of early versus selectively invasive strategy in patients with acute coronary syndromes without ST-segment elevation. Int J Cardiol 2009, 131(2):204-211.
12. Polanczyk C.A., Schneid S., Imhof B.V., Furtado M., Pithan C., Rohde L.E., et al. Impact of redefining acute myocardial infarction on incidence, management and reimbursement rate of acute coronary syndromes. Int J Cardiol 2006, 107(2):180-187.
13. Choi Y.F., Wong T.W., Lau C.C. The diagnostic value and cost-effectiveness of creatine kinase-MB, myoglobin and cardiac troponin-T for patients with chest pain in emergency department observation ward. Hong Kong J Emerg Med 2004, 11(2):85-90.
14. Goodacre S., Calvert N. Cost effectiveness of diagnostic strategies for patients with acute, undifferentiated chest pain. Emerg Med J 2003, 20(5):429-433.
15. Caragher T.E., Fernandez B.B., Barr L.A. Long-term experience with an accelerated protocol for diagnosis of chest pain. Arch Pathol Lab Med 2000, 124(10):1434-1439.
16. Kunz R., Oxman A.D. The unpredictability paradox: review of empirical comparisons of randomised and nonrandomised clinical trials. BMJ 1999, 317:1185-1190.
17. Sacks H., Chalmers T.C., Smith H. Randomized versus historical controls for clinical trials. Am J Med 1982, 72:233-240.
18. Mills N., Churchhouse A.M.D., Lee K.K., Anand A., Gamble D., Shah A.S.V., et al. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA 2011, 305:1210-1216.
19. Thygesen K., Alpert J.S., White H.D. Universal definition of myocardial infarction. J Am Coll Cardiol 2007, 50:2173-2195. on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction.
20. Lipinski, Baker N., Alarcon R.E., Torguson R., Epstein S., Aldous S., et al. Comparison of conventional and high-sensitivity troponin in patients presenting to the emergency department with chest pain: a collaborative meta-analysis. American College of Cardiology Annual Meeting, Washington DC, March 29, 2014 2014.
21. Ryan R.J., Lindsell C.J., Hollander J.E., O'Neil B., Jackson R., Schreiber D., et al. A multicenter randomized controlled trial comparing central laboratory and point-of-care cardiac marker testing strategies: the Disposition Impacted by Serial Point of Care Markers in Acute Coronary Syndromes (DISPO-ACS) trial. Ann Emerg Med 2009, 53:321-328.
22. National Institute for Health and Clinical Excellence Guide to the methods of technology appraisal 2008.